67-07-2Relevant articles and documents
Meyerhof
, p. 377 (1944)
Synthesis technology of creatine phosphate sodium
-
Paragraph 0061; 0062; 0064, (2018/03/01)
The invention provides a synthesis technology of creatine phosphate sodium. The technology comprises the following steps: reacting creatine monohydrate with phosphoric acid in ethanol to obtain ethanol-insoluble creatine phosphate; and carrying out a refluxing reaction on the creatine phosphate in an ethyl acetate solvent with 4-dimethylpyridine (DMAP) as a creatine phosphorylation reaction catalyst and dicyclohexylcarbodiimide (DCC) as a reaction dehydrant to obtain phosphorylated creatine, carrying out alkaline hydrolysis on the phosphorylated creatine in an aqueous solution of sodium hydroxide, filtering the obtained alkaline hydrolysis product, and adding ethanol to the obtained filtrate to obtain the creatine phosphate sodium. The whole technology is a normal-temperature and normal-pressure technology basically, and has the advantages of low energy consumption and high single-step reaction yield. Water-insoluble 1,3-dicyclohexylurea (DCU) completely formed by the DCC dehydrant in the alkaline hydrolysis workshop section can be filtered out, and the ethanol is directly added to the aqueous solution to precipitate a high-quality creatine phosphate disodium salt. The ethyl acetate and anhydrous ethanol used in the technology can be recycled. The discharge capacity of wastewater in the whole technology is small.
Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
-
, (2008/06/13)
A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.